These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Changes in pulmonary artery pressure in infants with respiratory distress syndrome after treatment with Exosurf. Rogers D Arch Dis Child Fetal Neonatal Ed; 1996 Mar; 74(2):F151. PubMed ID: 8777670 [No Abstract] [Full Text] [Related]
8. Retrospective search for bleeding diathesis among premature newborn infants with pulmonary hemorrhage after synthetic surfactant treatment. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group. Long W; Corbet A; Allen A; McMillan D; Boros S; Vaughan R; Gerdes J; Houle L; Edwards K; Schiff D J Pediatr; 1992 Feb; 120(2 Pt 2):S45-8. PubMed ID: 1735852 [TBL] [Abstract][Full Text] [Related]
9. Surfactant therapy for hyaline membrane disease: the Chandigarh experience. Narang A; Kumar P; Dutta S; Kumar R Indian Pediatr; 2001 Jun; 38(6):640-6. PubMed ID: 11418729 [No Abstract] [Full Text] [Related]
11. [Natural or synthetic surfactant in the treatment of neonatal respiratory distress syndrome]. Robertson B; Sangstad OD Tidsskr Nor Laegeforen; 1994 Feb; 114(5):590-1. PubMed ID: 8209345 [No Abstract] [Full Text] [Related]
12. Tracheal aspirate surface tension in babies with hyaline membrane disease: effects of synthetic surfactant replacement. McMillan DD; Singhal N; Shukla AK; Schürch S Pediatr Pulmonol; 1998 Sep; 26(3):173-82. PubMed ID: 9773912 [TBL] [Abstract][Full Text] [Related]
13. Lysis of red blood cells and alveolar epithelial toxicity by therapeutic pulmonary surfactants. Findlay RD; Taeusch HW; David-Cu R; Walther FJ Pediatr Res; 1995 Jan; 37(1):26-30. PubMed ID: 7700730 [TBL] [Abstract][Full Text] [Related]
14. Criteria for use of colfosceril (Exosurf) in neonates. Bhatt-Mehta V; Schumacher RE Clin Pharm; 1992 Apr; 11(4):355-7. PubMed ID: 1563234 [No Abstract] [Full Text] [Related]
15. Hyaline membrane disease (HMD) therapy in Latin America: impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. Rossello JD; Hayward PE; Martell M; Del Barco M; Margotto P; Grandzoto J; Bastida J; Peña J; Villanueva D J Perinat Med; 1997; 25(3):280-7. PubMed ID: 9288665 [TBL] [Abstract][Full Text] [Related]
16. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Husain AN; Siddiqui NH; Stocker JT Hum Pathol; 1998 Jul; 29(7):710-7. PubMed ID: 9670828 [TBL] [Abstract][Full Text] [Related]
18. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Phibbs RH; Ballard RA; Clements JA; Heilbron DC; Phibbs CS; Schlueter MA; Sniderman SH; Tooley WH; Wakeley A Pediatrics; 1991 Jul; 88(1):1-9. PubMed ID: 2057244 [TBL] [Abstract][Full Text] [Related]
19. Effect of institutional differences on study of surfactant in two centers. Etches PC; Peliowski A; Finer NN; Tierney AJ J Pediatr; 1991 Jul; 119(1 Pt 1):162-3. PubMed ID: 2066853 [No Abstract] [Full Text] [Related]
20. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Hudak ML; Martin DJ; Egan EA; Matteson EJ; Cummings NJ; Jung AL; Kimberlin LV; Auten RL; Rosenberg AA; Asselin JM; Belcastro MR; Donohue PK; Hamm CR; Jansen RD; Brody AS; Riddlesberger MM; Montgomery P Pediatrics; 1997 Jul; 100(1):39-50. PubMed ID: 9200358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]